Simon, Teresa A. http://orcid.org/0000-0003-4042-0715
Boers, Maarten
Hochberg, Marc
Baker, Nicole
Skovron, Mary L.
Ray, Nitesh
Singhal, Sanket
Suissa, Samy
Gomez-Caminero, Andres
Funding for this research was provided by:
Bristol-Myers Squibb (NA)
Article History
Received: 15 January 2019
Accepted: 5 September 2019
First Online: 8 November 2019
Ethics approval and consent to participate
: Not applicable
: Not applicable
: TAS and NB are employees and shareholders of Bristol-Myers Squibb. MB is a consultant for Bristol-Myers Squibb and has received consulting fees (< $10,000) from Pfizer, UCB, and Teva in the past 2 years. MH is a shareholder of Theralogix LLC, has received grant/research support (< $10,000) from the National Institutes of Health, and is a consultant for Bristol-Myers Squibb, EMD Serono, Genentech/Roche, Novartis, Pfizer, and UCB. MLS and SSu are consultants to Bristol-Myers Squibb. NR and SSi are employees of Mu Sigma and have received research grants (< $10,000) from Bristol-Myers Squibb. AG-C is a shareholder of GlaxoSmithKline and Bristol-Myers Squibb and is an employee of Bristol-Myers Squibb.